Quality View on Injectable Product Considerations (20of35) Complex Generic Drugs - Sep. 25-26, 2019
Рет қаралды 1,090
Күн бұрынBita Mirzai-Azarm from CDER’s Office of Pharmaceutical Quality discusses critical attributes of injectable combination products including functionality attributes and quality attributes. She also provides points-to-consider for frequently asked questions.
Learn more at www.fda.gov/dr...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Visit www.fda.gov/cd... and www.fda.gov/cd... for news and a repository of training activities.
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
LinkedIn: / cder-small-business-an...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
U.S. Food and Drug Administration
Рет қаралды 1 М.
U.S. Food and Drug Administration
Рет қаралды 1,4 М.
U.S. Food and Drug Administration
Рет қаралды 1,2 М.
U.S. Food and Drug Administration
Рет қаралды 2,2 М.
U.S. Food and Drug Administration
Рет қаралды 1,1 М.
U.S. Food and Drug Administration
Рет қаралды 694
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) ...
U.S. Food and Drug Administration
Рет қаралды 983
U.S. Food and Drug Administration
Рет қаралды 847
U.S. Food and Drug Administration
Рет қаралды 833